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The role of glial cells in the pathogenesis of many neurodegenerative conditions of the
central nervous system (CNS) is now well established (as is discussed in other reviews
in this special issue of Frontiers in Neuropharmacology). What is less clear is whether
there are changes in these same cells in terms of their behavior and function in response
to invasive experimental therapeutic interventions for these diseases. This has, and will
continue to become more of an issue as we enter a new era of novel treatments which
require the agent to be directly placed/infused into the CNS such as deep brain stimulation
(DBS), cell transplants, gene therapies and growth factor infusions. To date, all of these
treatments have produced variable outcomes and the reasons for this have been widely
debated but the host astrocytic and/or microglial response induced by such invasively
delivered agents has not been discussed in any detail. In this review, we have attempted
to summarize the limited published data on this, in particular we discuss the small number
of human post-mortem studies reported in this field. By so doing, we hope to provide a
better description and understanding of the extent and nature of both the astrocytic and
microglial response, which in turn could lead to modifications in the way these therapeutic
interventions are delivered.
Keywords: gene therapy for neurodegenerative diseases, cell transplantation, deep brain stimulation, Alzheimer’s
disease, Huntington’s disease, Parkinson’s disease, astrocytes, microglia
INTRODUCTION
Over the last 30 years, there has been a burgeoning of new thera-
peutic approaches to treat chronic neurodegenerative conditions
of the central nervous system (CNS). These approaches have
essentially been of two main types:
(i) Better symptomatic agents most notably deep brain stimu-
lation (DBS) for Parkinson’s Disease (PD) as well as gene
therapy approaches (e.g., AAV2-GAD; ProSavin®; hAADC
gene therapy).
(ii) Restorative agents such as growth factor administration or
cell transplants. This has involved either directly infusing
growth factors into the CNS (e.g., GDNF in the case of PD)
or the use of viral delivery systems (e.g., AAV2-Neurturin). In
the case of cell therapies a number of different cell types have
been grafted into the diseased brain especially in patients
with PD (e.g., adrenal medulla; carotid body; ventral mesen-
cephalon, amongst others) and Huntington’s Disease (HD)
(fetal striatal cells).
Whilst the efficacy of these approaches has been the subject of
many reviews, one area that has received rather less attention
is the host response to these therapeutic agents. This involves
not only an anticipated and beneficial response (e.g., cell inte-
gration, fiber sprouting, synapse formation, and so on) but also
a glial reaction to it, involving both astrocytes and microglia.
In the adult CNS, astrocytes constitute the predominant glial
cell type that function to control the CNS environment by
removing excess ions and recycling neurotransmitters, support-
ing endothelial cells that form the blood-brain-barrier, as well
as playing a key role in tissue scarring and repair following
injury. In recent years, the importance of cross-communication
between astrocytes, as well as between astrocytes and neuronal
cells has started to be better understood. Microglial cells, in
contrast, have more of a phagocytic function but like astro-
cytes, are known to release cytokines in inflammatory/infectious
conditions. Whilst both astrocytes and microglia react to, and
convey messages within their immediate environment, they also
can communicate over extended distances through syncytial
networks.
In this review, we will discuss the extent to which the glial
response may limit, or possibly augment, the potential effects of
intracerebrally delivered therapeutic approaches for neurodegen-
erative disorders. The focus of this mini review will be largely
restricted to the astrocytic and microglial responses in human
post-mortem studies, as there is no published data on the oligo-
dendroglial response to these types of treatments. However,
because of the importance of pre-clinical data in this field,
we have also summarized studies that have reported on the
nature of the glial response in the context of DBS (Table 1),
neurotrophic therapies (Table 2), and neural grafting (Table 3)
in vivo.
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DEEP BRAIN STIMULATION AND THE GLIAL RESPONSE
In the last 20 years, DBS has been used to treat a range of neuro-
logical disorders, most notably in patients with advancing PD and
those with essential tremor refractory to medical therapy (Lyons,
2011). DBS involves applying high frequency stimulation (HFS)
via implanted electrodes into strategic CNS nuclei which serves to
modulate the output of these nuclei with therapeutic benefits in
the majority of patients. This benefit persists for many years and
has encouraged the adoption of this approach for a whole range of
new indications including neuropsychiatric conditions and pain,
as well as in earlier stage PD. However, the host CNS glial response
to the implantation of this foreign body and the HFS that it deliv-
ers has been the subject of only a few reports, especially in the
clinical field.
In contrast, there has been a significant amount of experimen-
tal work over the years to look at how the CNS reacts to chron-
ically implanted electrodes, although more often in the context
of micro-recording than DBS. This is because micro-recording is
a well-established method for studying CNS function and DBS
has been developed for use primarily in non-human primates and
man rather than rodents. Nevertheless, as one would expect, the
insertion of a metal electrode into the parenchyma of the brain
will induce an astrocytic response (both in terms of the number
and degree of astrocytes activated), the magnitude of which may
be dependent, in part, on the electrode architecture (Szarowski
et al., 2003; Groothuis et al., 2014), and the biomaterial being used
(Ereifej et al., 2011). Studies of this type have led some to look at
non-metallic electrodes with the hope that this will induce less
of a glial response (Ereifej et al., 2011). For example, stainless-
steel, as oppose to platinum-iridium or tungsten electrodes, are
more prone to electrolytic dissolution which may increase the
likelihood of local cell death and a secondary astroglial response
(Harnack et al., 2004).
In all cases, the astrocytic and microglial responses—which
typically include a change in cell morphology and density of acti-
vated cells as well as the release of various pro-inflammatory
molecules—are evident soon after implantation (Figure 1.1), per-
sist for years (Jarraya et al., 2003) and seem to occur indepen-
dently of where the electrode is placed in the brain and the clinical
condition for which it is being used (Moss et al., 2004). The extent
to which this reactive astroglial and microglial response changes
over time is unknown (although see Griffith and Humphrey,
2006), as are the effects that such changes have on the efficacy
of current delivered by the stimulating electrode. Nevertheless, a
number of experimental studies have shown that these glial reac-
tions could adversely affect electrode impedance and thus efficacy
(Spataro et al., 2005; Polikov et al., 2009; Frampton et al., 2010).
Indeed, there is even some evidence that chronically implanted
electrodes cause sustained local inflammation and neurodegener-
ation (McConnell et al., 2009). For example, in a study performed
in rodents, McConnell et al. demonstrated that heightened levels
of chronic inflammation correlated with increased neuronal and
dendritic loss, a phenomenon which was more pronounced at 16
weeks than at 8 weeks post-implantation. Remarkably, this local
but progressive neurodegeneration was accompanied by axonal
pathology, as evidenced by tau phosphorylation, a prominent
feature of neurodegenerative conditions. Exactly how this tau
pathology arises is unclear but it does suggest that inflammation
may be able to induce some forms of proteinopathy.
Additionally, in a recent paper by Vedam-Mai et al. they have
interestingly shown in patients that there are variable responses
to chronic DBS electrodes, ranging from minimal astrocytosis
and microglia activation in the majority of cases to the forma-
tion of a dense collagenous band at the electrode tip in at least
one case (Vedam-Mai et al., 2012b). In this paper, the authors
comment on the possibility of gliotic encapsulation altering elec-
trical thresholds of the stimulating electrode and with this its
clinical efficacy—although this study would suggest that this is a
rare event. Understanding and predicting such tissue responses
to the stimulating and recording electrodes, or even just can-
nula guidewires, is critical as the magnitude of the foreign body
response can lead to electrode failure (Groothuis et al., 2014) and
suboptimal clinical outcomes. However, in this study, they did not
look to see whether the inflammation induced altered the pathol-
ogy within the brain, which is of course not straightforward in
patients with pre-existing neurodegenerative disorders.
Based on data of this type, some experimental studies have
sought tominimize this microglial and inflammatory response, or
so-called foreign body response, by using agents such as minocy-
cline and steroids in combination with the stimulating electrode
(Rennaker et al., 2007; Zhong and Bellamkonda, 2007) as well as
nanoparticle delivery systems (Kim andMartin, 2006; Mercanzini
et al., 2010). These different strategies are all predicated on the
grounds that suppressing the microglial/inflammatory response
to DBS will improve the brain-electrode interface in these chron-
ically implanted micro-electrodes and thus maintain efficacy.
Whether this is really a problem in patients with DBS is unknown
(see above and Vedam-Mai et al., 2012a,b), but one interesting
study by Hirshler et al. (2010) (see also Table 1) in rats showed
that merely inserting an electrode into the brain could induce
widespread and chronic (i.e., over weeks) neuroinflammation
which was correlated with deficits in cognitive function—deficits
which are also seen in patients who have had DBS (Witt et al.,
2008). No such studies using microglia markers and positron
emission tomography (PET) have been performed clinically,
although a recent study found that in patients with DBS of
the pedunculopontine nucleus, there was an improvement in
cognition in association with improvements in cortical activity
as measured by fluorodeoxyglucose (FDG)-PET (Stefani et al.,
2010). This aspect of DBS, namely its ability to induce widespread
inflammation (i.e., not just at the site of implantation of the elec-
trode) across whole neural networks may prove to be much more
important in understanding the positive and negative effects on
cognition in the large number of conditions for which it is now
being used. However, this is clearly complicated by the fact that
the stimulation itself will alter the function of neural networks
directly, as has been seen in studies looking at cognitive func-
tion in patients in receipt of subthalamic DBS (Funkiewiez et al.,
2006).
However, more recently, others have argued that the induc-
tion of a significant astrocytic response actually enhances any
DBS-mediated effects (Fenoy et al., 2014). Fenoy et al. suggest
that the inevitable stimulation of astrocytes by DBS can set in
motion the release of gliotransmitters (e.g., glutamate, adenosine,
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FIGURE 1 | Schematic depicting the astroglial and microglial responses
to a variety of invasive experimental therapeutic approaches being
trialed for neurodegenerative disorders (1–3). (4) Potential cell
interactions that may further influence the outcome of the therapeutic
intervention, or, that could be used to potentiate the effects of these
therapies. For example the astrocytic response may lead to the release of
trophic factors, the modulation of local blow flow as well as the activation
of axonal circuits via tripartite synapses. The microglial response may
produce both neuroprotective and neurotoxic products, all of which may
impact not only on local neurons but also on local vasculature to influence
the efficacy of the delivered therapeutic agent. Note: p-zone refers to areas
of the graft expressing markers for striatal cells.
and D-serine) that can in turn trigger axonal activation which
mediates part of the therapeutic benefits of the stimulation. For
example, application of adenosine A1-receptor antagonists abol-
ishes HFS-induced suppression of thalamic neuronal activity.
More specifically, adenosine, which results from the conversion
of ATP by astrocytes, significantly increases in the electrodes’
surroundings, endorsing its role in stimulation-mediated effects
on tremor (Bekar et al., 2008). In support of this, the release of
glutamate and adenosine both terminate oscillations generated by
HFS in thalamic sites (Tawfik et al., 2010).
www.frontiersin.org July 2014 | Volume 5 | Article 139 | 3
Cicchetti and Barker Glial response to experimental therapeutics
Table 1 | Glial response to DBS and electrode implantation in in vivo models.
References Species Condition Target Type of Period of experimentation/ Nature of the glial
site stimulation observation response
Han et al., 2012 Cat Normal Inferior colliculus Chronic 3–18 months Observable astrogliosis
near the probe at 2
months, but reduced at 5
months
Morimoto et al.,
2011
Male Wistar rat Stroke Striatum Chronic 1 week Diminished microglial
activation with
stimulation
Hirshler et al.,
2010
Male
Sprague-Dawley
rat
Normal Subthalamic
nucleus
Electrode
implantation only
1–8 weeks Astrocytic and microglial
activation; more
significant in cortex,
striatum, and thalamus
Baba et al., 2009 Wistar rat Stroke Cortex (ischemic
boundary)
Chronic 1 week Diminished microglial
and astrocytic
proliferation
Harnack et al.,
2008
Male Wistar rat Normal Subthalamic
nucleus
Chronic 3 weeks Increased number of
GFAP+ astrocytes at all
anatomical sites as well
as thickening of
processes
Leung et al., 2008 Rat Normal Cortex Electrode
implantation only
12 weeks Observable activated
microglia attached to the
electrodes’ external
coatings
Biran et al., 2007 Male Fischer-344
rat
Normal Cortex Electrode
implantation only
2–4 weeks Microglia and astrocyte
activation around the
electrode
Lenarz et al., 2007 Cat Normal Inferior colliculus Semi-chronic
(4 h/day)
Implantation: 3 months
Stimulation: 60 days beginning 4
weeks post-implantation
Increased GFAP+ cell
density around the
electrode (greater with
the stimulated than the
non-stimulated electrode)
Stice et al., 2007 Female
Sprague-Dawley
rat
Normal Cortex Electrode
implantation only
2 and 4 weeks Astrocytic scar around
the electrodes
Griffith and
Humphrey, 2006
Rhesus macaque Normal Cortex Electrode
implantation only
3 months and 3 years Persistent reactive
astrogliosis around the
electrodes (3 months to
3 years). Transient
microglial reaction
(present at 3 months but
not at 3 years)
Biran et al., 2005 Male Fischer-344
rat
Normal Cortex Electrode
implantation only
4 weeks Persistent activated
microglia around the
electrode
Kim et al., 2004 Male Fischer-344
rat
Normal Striatum Electrode
implantation only
4 weeks Significant increase in
activated microglia in all
brain regions
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Astrocytes, which have the capacity to interact with up to 2
million synapses in the human brain, can have a profound effect
on synaptic activity as well as other astrocytes across large neu-
ral networks (Oberheim et al., 2006). The contact that astrocytes
have with blood vessels also uniquely enables them to regulate
local blood flow in response to increased neuronal activity, which
againmay help explain the beneficial effects of DBS (Takano et al.,
2006). Using in vivo two-photon imaging and photolysis, the
authors elegantly demonstrated the association between increases
in Ca2+ levels in astrocytic end feet with vasodilation, a pro-
cess which more specifically involves COX-1 metabolites. Finally,
DBS can also promote the proliferation of “neurogenic astro-
cytes” which can differentiate into functional neurons (Vedam-
Mai et al., 2012a) (Figure 1). Taken together, this data suggests a
prominent role for astrocytes in DBS-mediated effects implying
that there may be an optimal balance in the astrocytic response,
in terms of positive and negative effects on the stimulated neural
pathways, which may in part be responsible for determining the
clinical success of this treatment.
In summary, DBS electrodes will induce an astrocytic and
microglial response (Figure 1.1) although the extent to which this
adversely affects their efficacy in patients is unproven. Indeed,
recent data may even suggest the opposite (Moro et al., 2010).
However, the data is limited and there is therefore a need to collect
systemically more information in this area and moves are afoot to
do this (Vedam-Mai et al., 2011), with the expectation that this
will enable us to better understand this hitherto poorly described
effect of DBS (Vedam-Mai et al., 2011).
NEUROTROPHIC THERAPIES AND THE GLIAL RESPONSE
GENE THERAPY
There are a number of gene therapy trials that have been
undertaken in PD which seek to either improve the delivery of
dopaminergic stimulation to the striatum; restore to normal the
abnormal circuitry of the basal ganglia or promote host repair
through rescuing dopaminergic neurons and their striatal inner-
vation (reviewed in Berry and Foltynie, 2011). Other gene therapy
trials have targeted HD (Bloch et al., 2004) and Alzheimer’s dis-
ease (AD) (Mandel, 2010). In this last respect, Nerve growth
Factor (NGF) transfected fibroblasts were used and one patient
died shortly after receiving the therapy for unrelated reasons. At
post-mortem, the brain showed surviving cells and NGF expres-
sion, and although the glial response to the therapy was not
explicitly studied, they did comment there was a minimal inflam-
matory and glial response, as evidenced by the fact that they
found a few granulomatous cells only (Tuszynski et al., 2005).
In the PD studies, again only a few patients have come to
post-mortem, so any data as to the host response to these virally
delivered agents is very limited andmost have concentrated on the
extent of tyrosine hydroxylase (TH) fiber sprouting and the vol-
ume of distribution of the therapeutic agent, as well as systemic
toxicity and local inflammation (e.g., Herzog et al., 2008, 2009;
Bartus et al., 2011). However, there are studies showing that these
agents may have a primary effect on the astrocytic compartment
and that this is the route by which they actually rescue neurons.
For example, Hauck et al. (2006) showed that GDNF works indi-
rectly on photoreceptors to rescue them via Mueller glial cells,
and so unlike other invasive therapies, part of their efficacy may
actually be enhanced through the host glial compartment.
Overall, evidence to date would suggest that the viral deliv-
ery of neuroactive substances to the CNS induces very little glial
and inflammatory cell responses, including AAV2-Neurturin (Jeff
Kordower; Personal Commun.) (Figure 1.2) as well as pre-clinical
reports pertaining to this field (Table 2).
DIRECT NEUROTROPHIC FACTOR INFUSION
The direct infusion of GDNF into the brain of patients with
PD has been the subject of a number of trials. This was ini-
tially undertaken using an intraventricular delivery approach that
proved ineffective (Nutt et al., 2003), almost certainly because the
agent failed to reach the dopaminergic neurons and their projec-
tions. This would be consistent with the single post-mortem case
from this study showing no evidence of regeneration within the
affected nigrostriatal pathway (Kordower et al., 1999). This was
then followed by a number of studies in which GDNF was directly
infused into the brain parenchyma with variable efficacy—the
open label studies showed benefits whilst a double blind placebo
controlled study showed no such effects (Gill et al., 2003; Patel
et al., 2005; Slevin et al., 2005, 2007; Lang et al., 2006). Although
there are various reasons as to why this may have occurred
(Barker, 2006), it is of interest to know whether the infusion pro-
voked a glial reaction. This is important not only to see the extent
to which chronically implanted catheters delivering neuroactive
agents induce a glial response but, given that astrocytes them-
selves can actually release neurotrophic factors (e.g., Iravani et al.,
2012), it is also critical to know whether they may also be capable
of enhancing any regenerative response.
In the single post-mortem case looking at intra-parenchymal
GDNF delivery in a patient with PD, there was evidence of host
TH fiber sprouting around the catheter tip with a low grade
astrocytic, microglial and T-cell response (Love et al., 2005).
This patient showed a 38% improvement in their contralateral
UPDRS (Unified Parkinson’s disease rating scale) “off” motor
score with a 91% increase in Fluoro-dopa signal in the infused
posterior putamen. He died of a myocardial infarction, 3 months
after stopping the GDNF therapy that he had been receiving
for 43 months. Neuropathologically, there was a slight astroglio-
sis around the catheter track and tip with a few MHC class II
expressing microglia and where this was most intense, there was
a reduction in the synaptic protein, synaptophysin. Overall, the
glial response to the chronic infusion of GDNF was localized.
NEURAL GRAFTING AND THE GLIAL RESPONSE
The experimental approach of cell transplantation is one in
which the glial response has been more specifically addressed.
Two distinct types of cell transplantation have been tested in the
clinic—cell suspensions, prepared by mechanically dissociating
the cells prior to implantation (Lindvall et al., 1990; Mendez et al.,
2002; Freeman and Brundin, 2006) and solid grafts, where donor
tissue is transplanted as small pieces (Freeman et al., 1995, 2000;
Kordower et al., 1997; Olanow et al., 2003; Freeman and Brundin,
2006; Cicchetti et al., 2009). Each of these strategies is associated
with a different pattern and intensity of gliosis. In addition, dif-
ferent cell types may induce different host responses, depending
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Table 2 | Glial response to neurotrophic therapies in in vivo models.
References Species Condition Vector Delivery site Nature of the glial
response
Rahim et al., 2012 MF1 mouse (fetal) Normal Ad5 and AAV
pseudotypes 2/5, 2/8, 2/9
Lateral ventricle
(trans-uterine
injection)
No significant
microglia-mediated
immune response (with
any of the vectors)
Louboutin et al., 2011 Rhesus macaque Normal Recombinant
SV40-derived vector
Caudate nucleus No microglia or astrocyte
reactions
Rahim et al., 2011 MF1 mouse (fetal
and neonatal)
Normal AAV pseudotype 2/9 Intravenous No microglia-mediated
immune response
Hadaczek et al., 2010 Male Rhesus
macaque
PD (MPTP lesion) AAV Striatum No signs of
neuroinflammation or
reactive gliosis up to 8
years
Lattanzi et al., 2010 Mouse Globoid cell or
metachromatic
leukodystrophy
Lentivirus (coding for
beta-
galactocerebrosidase or
arylsulfatase A)
External capsule Decrease in activated
astrocytes and microglia
Snyder-Keller et al., 2010 B6.HDR6/1 mouse HD AAV2/1 (delivering
anti-htt scFv-C4)
Striatum Modest glial reaction
(activated microglia) at
the injection site
Toupet et al., 2008 C57Bl/6J mouse Prion disease Lentivirus Hippocampus Remarkable decrease in
astrogliosis
Louboutin et al., 2007 Female
Sprague-Dawley rat
Normal Recombinant
SV40-derived
Caudate-
putamen or
lateral ventricle
Increased number of
astrocytes along the
needle track (suggested
to be reparative gliosis in
response to the minor
lesion provoked by the
needle)
Zou et al., 2001 Male Fischer-344 rat Aged brain hdAdv and fgAdv Intraventricular
or hippocampus
Activation of microglia
and astrocytes at
injection sites: lower with
hdAdv than with fgAdv
Driesse et al., 1998 Rhesus macaque Normal Adenovirus Frontal lobe
white matter
(unilateral)
Astrocyte activation
Abbreviations: AAV, Adeno-associated virus; Ad5, Adenovirus serotype 5; fgAdv, first-generation adenoviral vectors; HD, Huntington’s disease; hdAdv, Helper-
dependent adenovirus; htt, huntingtin; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease.
on their source of origin, preparation, and mode of implantation
(see Table 3).
In PD, various post-mortem analyses conducted in trans-
planted patients have shown that solid grafts evoke a more robust
and durable immune response in comparison to cell suspen-
sions (Kordower et al., 1997; Olanow et al., 2003; Mendez et al.,
2005, 2008; Freeman and Brundin, 2006; Cooper et al., 2009),
a finding which is further supported by observations collected
in grafted animal models of the disease (Leigh et al., 1994; see
also Table 3). Few microglial cells are observed around the needle
track with only a mild response around the graft deposits them-
selves. Similarly, the astrocytic response, which accompanies cell
suspension grafts, is predominantly confined to the borders of the
graft, with the core of the transplant largely devoid of this cell type
(Figure 1.3).
Histological analyses in HD patients transplanted with solid
embryonic neural grafts show microglial activation, particularly
around the transplant and within the grafted areas expressing
striatal markers (referred to as p-zones). Importantly, this sig-
nificant microglial cuffing is still present 12 years following
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Table 3 | Glial response to neural grafting in in vivo models.
References Species Condition Cell type Implantation site Nature of the glial response
De Vocht et al., 2013 Male FVB/NCrl
mouse
Normal Autologous
mesenchymal stromal
cells
Right hemisphere M1-microglia and severe
astrogliosis surrounding the
graft (2 weeks post-tp)
Ma et al., 2013 APP/PS1 double
transgenic
mouse
AD Adipose-derived
mesenchymal stem cells
Hippocampus and
cortex
Increased number of
activated microglia in
transplanted regions
Osman et al., 2013 Mouse Irradiated Syngenic enteric neural
stem/progenitor cells
Hippocampus Microgliosis and astrogliosis
associated with grafted cell
clusters
Tripathy et al., 2013 Male
Sprague-Dawley
rat
PD Differentiated neurons
from murine embryonic
stem cells
Striatum Increased expression of
microglia-derived factors
(CD11b and Iba1).
Astrocytosis in the grafted
region. Increase in GDNF
Mosher et al., 2012 C57Bl/6J mouse Normal Mouse neural progenitor
cells
Striatum Increased number of Iba1+
microglia in transplanted
regions
Praet et al., 2012 C56Bl/6 mouse Normal and
cuprizone-treated
Neural stem cells Below the capsula
externa
Extensive invasion of GFAP+
astrocytes and Iba1+
microglia (few CD11b+)
within graft sites. Astrocytic
scar surrounding graft
Khoo et al., 2011 Wistar Ob rat PD (6-OHDA lesion) Bone marrow-derived
human mesenchymal
stem cells
(undifferentiated and
neuronal-primed)
Striatum and
substantia nigra
Iba-1+ microglia and GFAP+
astrocytes surrounding the
grafts (7 days post-tp)
Coyne et al., 2006 Female
Sprague-Dawley
rat
Normal Allogeneic marrow
stromal cells
Hippocampus or
striatum
Massive infiltration of ED1+
microglia leading to graft
rejection. Marked astrogliosis
surrounding grafts
Muraoka et al., 2006 Male Fischer
344 rat
Normal Autologous vs. allogeneic
neural stem cells
Hippocampus Astrocyte and microglia
reactivity in the host tissue
(lower in autologous than in
allogeneic tp)
Jiang et al., 1999 Monkey PD Microencapsulated rat
myoblasts transfected
with the tyrosine
hydroxylase gene
Striatum No obvious gliosis around
microcapsules
Dunnett et al., 1998 R6/2 mouse HD Syngenic striatal cell
suspension
Striatum Modest astroglial reaction at
the graft-host border
Pennell and Streit,
1997
Rat Normal Embryonic neural cell
suspension (whole, or
microglial and endothelial
cell-depleted)
Striatum Ameboid microglial cells
within grafts early post-tp. By
30 days post-tp, microglia
display a resting phenotype
within grafts
(Continued)
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Table 3 | Continued
References Species Condition Cell type Implantation site Nature of the glial response
Barker et al., 1996 Female
Sprague-Dawley
rat
PD (6-OHDA lesion) Embryonic ventral
mesencephalic tissue
Striatum Transient astrogliosis and
microglial reaction
surrounding grafts
Kosno-Kruszewska
et al., 1996
Rat Normal Cryopreserved ventral
mesencephalic tissue
Striatum Similar glial scar in both
grafted and sham-lesion
conditions
Duan et al., 1995 Female
Sprague-Dawley
rat
Normal Dissociated embryonic
ventral mesencephalic:
(murine syngeneic,
allogeneic, or
xenogeneic)
Striatum Similar reactions in syngeneic
and allogeneic: activated
microglia infiltration on day 4,
decreasing at 6 weeks. More
intense reaction in xenografts
leading to rejection
Helm et al., 1993 Female Rhesus
macaque
HD (ibotenic acid
lesion)
Monkey fetal neostriatal
neurons
Striatum Dense gliosis of degenerating
grafts at 8 months post-tp
Abbreviations: AD, Alzheimer’s disease; GDNF, Glial cell line derived neurotrophic factor; HD, Huntington’s disease; PD, Parkinson’s disease; tp, transplantation;
6-OHDA, 6-hydroxydopamine.
transplantation (Cicchetti et al., 2009). As observed in cell sus-
pension grafts, solid piece transplants induce little astrogliosis
although a number of cells of a reactive phenotype are found
around the grafted tissue (Cisbani et al., 2013) (Figure 1.3). This
pattern of astroglial activation and distribution may have impor-
tant implications for the survival of the grafts long-term, as
astrocytes play not only a critical role in growth factor release
but also in glutamate buffering, and thus excitotoxicity (Cicchetti
et al., 2011).
Comparing the post-mortem analysis of HD and PD allo-
grafted tissue, irrespective of the type of graft implanted, there
appears to be a distinctly different glial reaction. In HD, there
seems to be a much more aggressive glial (both in terms of the
number of activated cells and their phenotype) response whilst
in PD, the evidence would suggest that the microglial response
is much less obvious. Therefore, transplantation in different
diseases may produce different glial responses which in turn may
influence the long term survival, integration and outcome of the
grafted issue (Cicchetti et al., 2011, 2014).
Furthermore, we have recently shown the presence of mutant
huntingtin protein aggregates within genetically unrelated grafted
tissue in HD patients. This observation, which is similar to that
reported earlier with the discovery of lewy bodies in grafted fetal
ventral mesencephalon tissue in PD patients, could also result,
at least in part, from oxidative stress and the host inflammatory
response induced by the graft (Li et al., 2008; Cicchetti et al.,
2014).
Taken together, it is possible that the host response to solid
grafts in the absence of immunosuppression (which was restricted
to the first 6 months following transplantation in those HD
post-mortem cases described above) generates enhanced anti-
genic stimulation and a stronger immunological/inflammatory
response than with suspension grafts (Kordower et al., 1997;
Olanow et al., 2003; Mendez et al., 2005, 2008; Freeman and
Brundin, 2006; Redmond et al., 2008). Indeed, the type and
duration of immunosuppressive treatment is likely to contribute
to some of the discrepancies in the immune/glial responses
observed using these different transplants. Nevertheless, the accu-
mulating evidence of an attenuated glial response following trans-
plantation of cell suspension grafts favors their use in future clin-
ical cell transplant programs in patients with neurodegenerative
disorders (Freeman and Brundin, 2006).
CONCLUSION
There are now a number of new therapies emerging for the
treatment of chronic neurodegenerative disorders of the CNS
which are invasive but seek to restore to normal the dysfunc-
tional circuits that underlie these conditions. These approaches
have generally used a targeted intracerebral delivery of a neu-
roactive substance or therapeutic device. To date, these therapies
have produced mixed results and many explanations to account
for this have been put forward including patient selection, dis-
ease stage and subtype, mode of delivery, dose given, trial design,
and the nature and timing for the primary end-points. However,
another area that requires further investigation is the glial and
inflammatory response to the novel therapeutic agent as this may
impact on its efficacy. To date there are very few studies looking
at this and in this review we have sought to highlight this with
reference to the limited literature on the microglial and astrocytic
reactions to these therapies. At the present time, such responses
seem likely to be less of an issue with growth factor infusions and
gene therapies—although thismay simply reflect the limited post-
mortem analyses on this to date—but may be highly relevant for
the short and long term viability of neural transplants as well as
DBS efficacy, and to a greater magnitude than originally thought.
The only way such information can meaningfully be obtained
is through the detailed analyses of the post-mortem cases that
can be made available by such trials and which will allow us to
understand which cells are affected and to what extent. Indeed,
one of the critical questions will be the extent to which each cell
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type influences the behavior of another, as it is now clear that
there is a dialog between the glial cells, neurons, and vasculature
(Figure 1.4). An improved understanding of these interactions
may ultimately impact on our ability to better treat patients using
these novel approaches as well as modifications as to how they are
can be optimally delivered.
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